Morgan Stanley Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics (NASDAQ:DNLI) had its target price increased by equities research analysts at Morgan Stanley from $40.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price target points to a potential upside of 108.14% from the stock’s previous close.

Other analysts have also recently issued research reports about the stock. HC Wainwright upped their price target on shares of Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday. Wolfe Research assumed coverage on Denali Therapeutics in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Robert W. Baird upped their target price on Denali Therapeutics from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Thursday. UBS Group assumed coverage on Denali Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating for the company. Finally, Stifel Nicolaus boosted their price target on Denali Therapeutics from $34.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.82.

Denali Therapeutics Trading Down 10.2%

NASDAQ:DNLI traded down $2.29 during trading hours on Thursday, hitting $20.18. 1,983,249 shares of the company were exchanged, compared to its average volume of 1,747,152. The stock has a market capitalization of $3.20 billion, a price-to-earnings ratio of -6.77 and a beta of 1.02. Denali Therapeutics has a one year low of $10.57 and a one year high of $23.77. The company has a fifty day simple moving average of $20.41 and a 200 day simple moving average of $17.80. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same period in the prior year, the company earned ($0.67) EPS. Sell-side analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the completion of the sale, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the sale, the insider owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Groupama Asset Managment boosted its position in Denali Therapeutics by 11.7% during the fourth quarter. Groupama Asset Managment now owns 151,591 shares of the company’s stock worth $2,503,000 after purchasing an additional 15,833 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of Denali Therapeutics by 28.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after purchasing an additional 1,615,565 shares during the period. Invesco Ltd. lifted its stake in shares of Denali Therapeutics by 17.0% during the 4th quarter. Invesco Ltd. now owns 291,936 shares of the company’s stock valued at $4,820,000 after buying an additional 42,469 shares in the last quarter. Vestal Point Capital LP purchased a new position in Denali Therapeutics in the 4th quarter valued at approximately $7,677,000. Finally, Virtus Investment Advisers LLC grew its stake in Denali Therapeutics by 94.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 14,795 shares of the company’s stock valued at $244,000 after buying an additional 7,171 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics News Roundup

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA accelerated approval of AVLAYAH — first FDA‑approved, brain‑penetrant enzyme replacement therapy for Hunter syndrome; includes a Rare Pediatric Disease Priority Review Voucher and supports Denali’s TransportVehicle™ platform. GlobeNewswire: FDA Approval
• Positive Sentiment: Goldman Sachs raised its price target to $40 and reiterated a Buy — represents sizable upside vs. current levels and signals institutional conviction. Benzinga: Goldman Sachs PT Raise
• Positive Sentiment: Stifel Nicolaus raised its target to $41 and moved to Buy — another high target lift adding upward analyst momentum. Benzinga: Stifel PT Raise
• Positive Sentiment: HC Wainwright bumped its target to $42 (Buy) and BTIG raised to $38 (Buy); Robert W. Baird raised to $32 (Outperform) — broad analyst upgrades today increase headline upside consensus. Benzinga: Analyst Raises TickerReport: BTIG Raise
• Neutral Sentiment: Denali is hosting a conference call/webcast today at 12:30 PM ET to discuss the FDA approval and launch plans — investors should listen for commercialization cadence, launch timing, pricing/reimbursement plans and supply capacity. Investor Webcast
• Neutral Sentiment: Short‑interest data reported in public feeds is effectively zero/ambiguous for late March — no clear short squeeze signal from the filings. (Reports appear to show 0 shares short, which is likely a reporting artifact.)
• Negative Sentiment: Accelerated approval is based on a biomarker (CSF heparan sulfate); continued approval may be contingent on confirmatory Phase 2/3 COMPASS results — this creates regulatory and commercialization execution risk. GlobeNewswire: Approval Details & COMPASS
• Negative Sentiment: Safety and tolerability issues — infusion‑related reactions, risk of hypersensitivity/anaphylaxis and other adverse events noted in prescribing information — could affect uptake and reimbursement. GlobeNewswire: Safety Info
• Negative Sentiment: Insider selling disclosed in recent summaries (executive sales cited) and mixed institutional moves are potential near‑term selling pressure factors. Quiver: Insider & Institutional Activity

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.